1
Sergei M Gryaznov, Ronald G Schultz, Jer kang Chen: Oligonucleotide N3.fwdarw.P5 phosphoramidates. Lynx Therapeutics, Stephen C Macevicz, John D Mendlein, Vincent M Powers, October 12, 1999: US05965720 (189 worldwide citation)

Modified oligonucleotides 3'-NHP(O)(O.sup.-)O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form m ...


2
Sergei M Gryaznov, Ronald G Schultz, Jer kang Chen: Oligonucleotide N3.fwdarw.P5 phosphoramidates: triplex DNA formation. Lynx Therapeutics, January 7, 1997: US05591607 (136 worldwide citation)

Modified oligonucleotides 3'-NHP(O)(O.sup.-)O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form m ...


3
Sergei M Gryaznov, Ronald G Schultz, Jer Kang Chen: Oligonucleotide N3.fwdarw.P5 phosphoramidates: hybridization and nuclease resistance properties. Lynx Therapeutics, May 20, 1997: US05631135 (128 worldwide citation)

Modified oligonucleotides 3'-NHP(O)(O.sup.-)O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form m ...


4
Sergei Gryaznov, Ronald G Schultz: Oligo-2-fluoronucleotide N3->P5 phosphoramidates. Lynx Therapeutics, Stephen C Macevicz, Vincent M Powers, November 4, 1997: US05684143 (41 worldwide citation)

A new class of oligonucleotide N3'.fwdarw.P5' phosphoramidates having 2' fluoro substituents are provided that have superior acid stability. The invention includes oligo-2'-fluoronucleotide N3'.fwdarw.P5' phosphoramidates, methods of synthesis, and duplexes and triplexes formed with DNA and RNA. Com ...


5
Bernard L Hirschbein, Karen L Fearon, Sergei M Gryaznov, Sarah N McCurdy, Jeffery S Nelson, Ronald G Schultz: Solid phase synthesis of oligonucleotide N3-P5 phosphoramidates. Lynx Therapeutics, Stephen C Macevicz, Vincent M Dehlinger & Associates Powers, October 20, 1998: US05824793 (18 worldwide citation)

The invention provides a method of synthesizing oligonucleotide N3'.fwdarw.P5' phosphoramidates using an amine-exchange reaction of phosphoramidites in which a deprotected 3'-amino group of a solid phase supported oligonucleotide chain is exhanged for the amino portion of a 5'-phosphoramidite of an ...


6
Bernard L Hirschbein, Karen L Fearon, Sergei M Gryaznov, Sarah N McCurdy, Jeffrey S Nelson, Ronald G Schultz: Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates. Lynx Therapeutics, Stephen C Macevicz, Vincent M Powers, January 12, 1999: US05859233 (16 worldwide citation)

The invention provides a method of synthesizing oligonucleotide N3'.fwdarw.P5' phosphoramidates using an amine-exchange reaction of phosphoramidites in which a -deprotected 3'-amino group of a solid phase supported oligonucleotide chain is exhanged for the amino portion of a 5'-phosphoramidite of an ...


7
Gryaznov Sergei, Pongracz Krisztina, Matray Tracey: Thiophosphoramidates n3.fwdarw.p5 oligonucleotidiques: synthese et utilisation, Oligonucleotide n3.fwdarw.p5 thiophosphoramidates: their synthesis and use. Geron Corporation, Geron Corporation, SMART & BIGGAR, August 25, 2009: CA2382521 (1 worldwide citation)

Oligonucleotides with a novel sugar-phosphate backbone containing at least one internucleoside 3'-NHP(O)(S-)O-5' linkage, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive thiophosphoramidate oligonucleotides were found to retain the high RNA binding af ...


8
Eugeni A Namsaraev: Multiplex amplification methods. Affymetrix, November 14, 2017: US09816134

Compositions and methods for amplifying selected polynucleotides, including DNA and RNA, particularly in multiplex amplification reactions using common primers amplification. Generally, methods of the invention employ multiple steps such as template-specific hybridization, a linear amplification, pa ...


9
HIRSCHBEIN BERNARD L, FEARON KAREN L, GRYAZNOV SERGEI M, MCCURDY SARAH N, NELSON JEFFREY S, SCHULTZ RONALD G: SYNTHESE EN PHASE SOLIDE DE PHOSPHORAMIDATES N3.FWDARW.P5 OLIGONUCLEOTIDIQUES, SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3.FWDARW.P5 PHOSPHORAMIDATES. LYNX THERAPEUTICS, GERON CORPORATION, GOWLING LAFLEUR HENDERSON, November 10, 2009: CA2245666

The invention provides a method of synthesizing oligonucleotide N3'.fwdarw.P5' phosphoramidates using an amine-exchange reaction of phosphoramidites in which a deprotected 3'-amino group of a solid phase supported oligonucleotide chain is exchanged for the amino portion of a 5'-phosphoramidite of an ...